Insys Theraptcs Cmn (INSY) 15.98 $INSY
Pharmaceutical Studies & Trials of Individual Cannabinoids Aim to Develop Cannabis Strains That Specifically Target Cancer Pain and Nausea
CNW Group - Mon Jul 18, 7:30AM CDT
Medical Cannabis' biggest strength continues to be science as research and development drives sector forward with more consumers opting for marijuana over traditional treatment methods. Investors continue to pour millions of dollars into the newest studies and development of Medical Marijuana Applications as more states push towards legalization.
ABT: 45.31 (+0.56), INSY: 15.98 (+0.33), GWPH: 96.21 (+1.89), PFE: 37.30 (+0.41)
Today's Market Movers - Eleven Biotherapeutics, Insys Therapeutics, Himax Technologies and Broadcom
ACCESSWIRE - Wed Jul 06, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / July 6, 2016 / U.S. markets stumbled Tuesday after posting the largest weekly gain of 2016 last week. Stocks fell as investors continued to sell off their riskier assets, i.e. stocks and commodities, for safe have assets following Britain's exit from the European Union. A flood of buying has seen the yield on the benchmark 10-year U.S. Treasury note hit a historical low of 1.370 percent. On Tuesday, the Dow Jones Industrial Average and the S&P 500 Index posted declines of 0.61 percent and 0.68 percent, respectively. Register with us now for your free membership and gain access to our daily Market Movers stock reports at: http://rdinvesting.com/
INSY: 15.98 (+0.33), EBIO: 3.72 (-0.25), HIMX: 8.94 (-0.01)
Cannabis Attracting Big Business Operators as Multi-Billion Dollar Cannabis/Marijuana Industry Continues to Swell
PR Newswire - Wed Jul 06, 7:30AM CDT
Revenue forecasts for the cannabis industry in the United States continue to skyrocket as more states move towards legalization and companies develop innovative services and products to maximize earning potential. More and more big business entities are becoming involved in the lucrative cannabis sector as marijuana projects and opportunities explode in U.S.
XXII: 0.90 (+0.05), INSY: 15.98 (+0.33)
What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.40 (-0.15), INSY: 15.98 (+0.33), AGIO: 45.47 (+0.24), GNCA: 3.98 (-0.09)
Insys Therapeutics, Inc. to Present at Two Upcoming Conferences in June
GlobeNewswire - Thu May 26, 3:30PM CDT
Insys Therapeutics, Inc. ("Insys" or "the Company"
(NASDAQ:INSY) today announced that Darryl Baker, Chief Financial Officer, and Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical Officer, will present at two upcoming conferences in June as follows:
INSY: 15.98 (+0.33)
By 2020 Marijuana Sales are Expected to Reach Nearly $23 Billion With Predictions 2016 Will Be the Greenest Year in History; Company Executes International License Agreement
PR Newswire - Wed May 25, 7:30AM CDT
As illustrated by the Spring 2016 Marijuana Business Conference & Expo earlier this month, the numbers and momentum of cannabis in the US are undeniable. As revenues continue to climb into the billions, more research and development push the sector forward.According to the newly released 4th Edition State of Legal Marijuana Markets Report from from ArcView Market Research and New Frontier, a cannabis-focused data-analysis firm, much of the increase in sector is attributed to adult use market sales, which hit $1.3 billion last year alone. By 2020, adult use and medical marijuana sales are expected to reach nearly $23 billion.
INSY: 15.98 (+0.33), GWPH: 96.21 (+1.89)
Insys Therapeutics Successfully Completes Safety and Pharmacokinetic (PK) Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients
GlobeNewswire - Tue May 24, 5:50AM CDT
Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company" today announced that it has successfully completed its Phase 1/Phase 2 safety and pharmacokinetic (PK) study in pediatric subjects with treatment-resistant epilepsy.
INSY: 15.98 (+0.33)
Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board
GlobeNewswire - Mon May 16, 3:00PM CDT
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced that it has appointed Mr. Patrick Fourteau to its Board of Directors, where he will serve as Chairman of the Board.
INSY: 15.98 (+0.33), RPRX: 2.01 (-0.11)
Insys Therapeutics beats Street 1Q forecasts
Automated Insights - Thu Apr 28, 9:36AM CDT
CHANDLER, Ariz. (AP) _ Insys Therapeutics Inc. (INSY) on Thursday reported first-quarter net income of $2.4 million.
INSY: 15.98 (+0.33)
Insys Therapeutics Reports First Quarter 2016 Results
GlobeNewswire - Thu Apr 28, 5:50AM CDT
Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company" today announced financial results for the three-month period ended March 31, 2016.
INSY: 15.98 (+0.33)
Insys Therapeutics, Inc. to Present at Deutsche Bank 41st Annual Health Care Conference
GlobeNewswire - Tue Apr 26, 3:30PM CDT
Insys Therapeutics, Inc. ("Insys" or "the Company" (NASDAQ:INSY) today announced that Darryl Baker, Chief Financial Officer, and Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical Officer, will present at the Deutsche Bank 41 Annual Health Care Conference as follows:
INSY: 15.98 (+0.33), DB: 13.07 (-0.37)
Don't Get Smoked by These Pot Stocks on 4/20
David Bartosiak - Zacks Investment Research - Wed Apr 20, 3:45PM CDT
Pot is still illegal at the Federal level but there are some medicinal marijuana companies worth looking at
CARA: 6.07 (+0.14), JNJ: 125.52 (+0.29), INSY: 15.98 (+0.33), GWPH: 96.21 (+1.89), YUM: 89.44 (+0.02), PEP: 108.90 (-0.02)
What Falling Estimates & Price Mean for INSYS Therapeutics (INSY)
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 4:59PM CDT
INSYS Therapeutics has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off.
INSY: 15.98 (+0.33), ATRC: 15.30 (+0.11)
Insys Therapeutics to Report First Quarter 2016 Results
GlobeNewswire - Thu Apr 14, 3:30PM CDT
Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company" today announced that the Company will release its financial results for the first quarter 2016 on Thursday, April 28, 2016, before the U.S. financial markets open.
INSY: 15.98 (+0.33)
What Has Insys Theraepeutics Shares Crashing 20% Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 11, 2:57PM CDT
Image source: Insys Therapeutics. What: Following the release of preliminary first-quarter sales of its only commercialized drug, shares in Insys Therapeutics are collapsing 20.6% at 3:00 p.m. ET today. So what: Insys Therapeutics markets...
INSY: 15.98 (+0.33)
Insys Therapeutics Reports Preliminary Estimated Revenues from Subsys for the First Quarter 2016
GlobeNewswire - Mon Apr 11, 5:50AM CDT
Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company" today announced that its preliminary estimated revenues from Subsys (fentanyl sublingual spray) for the first quarter of 2016 will be in the range of $61 million to $62 million. Estimated revenues for the quarter reflect a decline in demand, as Subsys prescription volumes were down, as well as a reduction in wholesale inventory levels. The Company estimates the decrease in wholesale channel inventory levels to be in the range of $7 million.
INSY: 15.98 (+0.33)
NTRR: Colorado Aims to Curb Chemicals in Medical Cannabis
ACCESSWIRE - Tue Apr 05, 4:01AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 5, 2016 / Medical cannabis testing is set to become stricter than ever in Colorado, and Neutra Corp. (OTCQB: NTRR) is working to deliver solutions to help cultivators produce crops that comply with state regulations.
INSY: 15.98 (+0.33)
Scott + Scott, LLP Reminds Investors of April 4, 2016 Deadline to File Lead Plaintiff Papers in Insys Therapeutics (INSY) Securities Case
GlobeNewswire - Fri Apr 01, 3:44PM CDT
Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that April 4, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Insys Therapeutics, Inc. (NASDAQ:INSY). Insys investors are encouraged to contact Scott + Scott at (866) 326-5057 or email gjohnson@scott-scott.com to discuss their legal rights.
INSY: 15.98 (+0.33)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders of INSYS Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of April 4, 2016 - INSY
GlobeNewswire - Fri Apr 01, 2:30PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
INSY: 15.98 (+0.33)
Pharmaceutical Studies & Trials of Individual Cannabinoids Aim to Develop Cannabis Strains That Specifically Target Cancer Pain and Nausea
CNW Group - Mon Jul 18, 7:30AM CDT
Medical Cannabis' biggest strength continues to be science as research and development drives sector forward with more consumers opting for marijuana over traditional treatment methods. Investors continue to pour millions of dollars into the newest studies and development of Medical Marijuana Applications as more states push towards legalization.
ABT: 45.31 (+0.56), INSY: 15.98 (+0.33), GWPH: 96.21 (+1.89), PFE: 37.30 (+0.41)
Today's Market Movers - Eleven Biotherapeutics, Insys Therapeutics, Himax Technologies and Broadcom
ACCESSWIRE - Wed Jul 06, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / July 6, 2016 / U.S. markets stumbled Tuesday after posting the largest weekly gain of 2016 last week. Stocks fell as investors continued to sell off their riskier assets, i.e. stocks and commodities, for safe have assets following Britain's exit from the European Union. A flood of buying has seen the yield on the benchmark 10-year U.S. Treasury note hit a historical low of 1.370 percent. On Tuesday, the Dow Jones Industrial Average and the S&P 500 Index posted declines of 0.61 percent and 0.68 percent, respectively. Register with us now for your free membership and gain access to our daily Market Movers stock reports at: http://rdinvesting.com/
INSY: 15.98 (+0.33), EBIO: 3.72 (-0.25), HIMX: 8.94 (-0.01)
Cannabis Attracting Big Business Operators as Multi-Billion Dollar Cannabis/Marijuana Industry Continues to Swell
PR Newswire - Wed Jul 06, 7:30AM CDT
Revenue forecasts for the cannabis industry in the United States continue to skyrocket as more states move towards legalization and companies develop innovative services and products to maximize earning potential. More and more big business entities are becoming involved in the lucrative cannabis sector as marijuana projects and opportunities explode in U.S.
XXII: 0.90 (+0.05), INSY: 15.98 (+0.33)
What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.40 (-0.15), INSY: 15.98 (+0.33), AGIO: 45.47 (+0.24), GNCA: 3.98 (-0.09)
Insys Therapeutics, Inc. to Present at Two Upcoming Conferences in June
GlobeNewswire - Thu May 26, 3:30PM CDT
Insys Therapeutics, Inc. ("Insys" or "the Company"
(NASDAQ:INSY) today announced that Darryl Baker, Chief Financial Officer, and Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical Officer, will present at two upcoming conferences in June as follows: INSY: 15.98 (+0.33)
By 2020 Marijuana Sales are Expected to Reach Nearly $23 Billion With Predictions 2016 Will Be the Greenest Year in History; Company Executes International License Agreement
PR Newswire - Wed May 25, 7:30AM CDT
As illustrated by the Spring 2016 Marijuana Business Conference & Expo earlier this month, the numbers and momentum of cannabis in the US are undeniable. As revenues continue to climb into the billions, more research and development push the sector forward.According to the newly released 4th Edition State of Legal Marijuana Markets Report from from ArcView Market Research and New Frontier, a cannabis-focused data-analysis firm, much of the increase in sector is attributed to adult use market sales, which hit $1.3 billion last year alone. By 2020, adult use and medical marijuana sales are expected to reach nearly $23 billion.
INSY: 15.98 (+0.33), GWPH: 96.21 (+1.89)
Insys Therapeutics Successfully Completes Safety and Pharmacokinetic (PK) Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients
GlobeNewswire - Tue May 24, 5:50AM CDT
Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company"
today announced that it has successfully completed its Phase 1/Phase 2 safety and pharmacokinetic (PK) study in pediatric subjects with treatment-resistant epilepsy. INSY: 15.98 (+0.33)
Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board
GlobeNewswire - Mon May 16, 3:00PM CDT
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced that it has appointed Mr. Patrick Fourteau to its Board of Directors, where he will serve as Chairman of the Board.
INSY: 15.98 (+0.33), RPRX: 2.01 (-0.11)
Insys Therapeutics beats Street 1Q forecasts
Automated Insights - Thu Apr 28, 9:36AM CDT
CHANDLER, Ariz. (AP) _ Insys Therapeutics Inc. (INSY) on Thursday reported first-quarter net income of $2.4 million.
INSY: 15.98 (+0.33)
Insys Therapeutics Reports First Quarter 2016 Results
GlobeNewswire - Thu Apr 28, 5:50AM CDT
Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company"
today announced financial results for the three-month period ended March 31, 2016. INSY: 15.98 (+0.33)
Insys Therapeutics, Inc. to Present at Deutsche Bank 41st Annual Health Care Conference
GlobeNewswire - Tue Apr 26, 3:30PM CDT
Insys Therapeutics, Inc. ("Insys" or "the Company"
(NASDAQ:INSY) today announced that Darryl Baker, Chief Financial Officer, and Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical Officer, will present at the Deutsche Bank 41 Annual Health Care Conference as follows: INSY: 15.98 (+0.33), DB: 13.07 (-0.37)
Don't Get Smoked by These Pot Stocks on 4/20
David Bartosiak - Zacks Investment Research - Wed Apr 20, 3:45PM CDT
Pot is still illegal at the Federal level but there are some medicinal marijuana companies worth looking at
CARA: 6.07 (+0.14), JNJ: 125.52 (+0.29), INSY: 15.98 (+0.33), GWPH: 96.21 (+1.89), YUM: 89.44 (+0.02), PEP: 108.90 (-0.02)
What Falling Estimates & Price Mean for INSYS Therapeutics (INSY)
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 4:59PM CDT
INSYS Therapeutics has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off.
INSY: 15.98 (+0.33), ATRC: 15.30 (+0.11)
Insys Therapeutics to Report First Quarter 2016 Results
GlobeNewswire - Thu Apr 14, 3:30PM CDT
Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company"
today announced that the Company will release its financial results for the first quarter 2016 on Thursday, April 28, 2016, before the U.S. financial markets open. INSY: 15.98 (+0.33)
What Has Insys Theraepeutics Shares Crashing 20% Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 11, 2:57PM CDT
Image source: Insys Therapeutics. What: Following the release of preliminary first-quarter sales of its only commercialized drug, shares in Insys Therapeutics are collapsing 20.6% at 3:00 p.m. ET today. So what: Insys Therapeutics markets...
INSY: 15.98 (+0.33)
Insys Therapeutics Reports Preliminary Estimated Revenues from Subsys for the First Quarter 2016
GlobeNewswire - Mon Apr 11, 5:50AM CDT
Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company"
today announced that its preliminary estimated revenues from Subsys (fentanyl sublingual spray) for the first quarter of 2016 will be in the range of $61 million to $62 million. Estimated revenues for the quarter reflect a decline in demand, as Subsys prescription volumes were down, as well as a reduction in wholesale inventory levels. The Company estimates the decrease in wholesale channel inventory levels to be in the range of $7 million. INSY: 15.98 (+0.33)
NTRR: Colorado Aims to Curb Chemicals in Medical Cannabis
ACCESSWIRE - Tue Apr 05, 4:01AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 5, 2016 / Medical cannabis testing is set to become stricter than ever in Colorado, and Neutra Corp. (OTCQB: NTRR) is working to deliver solutions to help cultivators produce crops that comply with state regulations.
INSY: 15.98 (+0.33)
Scott + Scott, LLP Reminds Investors of April 4, 2016 Deadline to File Lead Plaintiff Papers in Insys Therapeutics (INSY) Securities Case
GlobeNewswire - Fri Apr 01, 3:44PM CDT
Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that April 4, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Insys Therapeutics, Inc. (NASDAQ:INSY). Insys investors are encouraged to contact Scott + Scott at (866) 326-5057 or email gjohnson@scott-scott.com to discuss their legal rights.
INSY: 15.98 (+0.33)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders of INSYS Therapeutics, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of April 4, 2016 - INSY
GlobeNewswire - Fri Apr 01, 2:30PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
INSY: 15.98 (+0.33)
